Characterization of Uterine Cancer in a Cohort of East African Patients [ID 1533]

INTRODUCTION: It is established that Black patients with uterine cancer have worse outcomes compared to other racial groups. However, many diverse cultural and ethnic groups are included within the cohort of “Black” patients that is traditionally described by national statistics. This study seeks to identify histologic subtypes, stage, treatment, recurrence, and survival of patients from East Africa with uterine cancer. METHODS: We identified patients born in (or immigrated from) East Africa diagnosed with uterine cancer between 2015 and 2022. Demographic, tumor, and treatment characteristics were obtained. Survival calculations were performed with Kaplan–Meier analysis. RESULTS: Sixty-one patients met inclusion criteria. Histology distribution included 27 patients (44.3%) with low-grade (LG) endometrial, 2 patients (3.3%) with sarcoma, and 32 patients with (52.5%) high-grade (HG) carcinoma. Most patients were from Somalia (n=41, 67%). Of patients with LG carcinoma, 92.6% had early stage (I–II), and 7.4% had advanced stage (III–IV). Low-grade disease had a 5-year overall survival (OS) of 84%. Of patients with HG carcinoma, 50% had early stage, and 50% had advanced stage. Patients with early-stage HG had recurrence of 43.8%, 2- and 5-year progression-free survival of 74% and 54%, respectively. High-grade disease had a 5-year OS of 73%. CONCLUSIONS/IMPLICATIONS: Over half of East African patients with uterine cancer had HG carcinoma or sarcoma. Recurrence rates were high, even in early-stage disease. This is the first study, to our knowledge, that characterizes uterine cancer in an East African cohort in the United States. Further molecular characterization of tumors and longitudinal studies are planned.